Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on September 3, 2021. The report details the entry into a Material Definitive Agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $20 million.
- Net Proceeds: Approximately $18.2 million (after placement agent fees and expenses, before estimated offering expenses).
- Securities Issued:
- 781,615 shares of Common Stock at $7.872 per share.
- 1,759,035 Pre-Funded Warrants at $7.8719 per warrant (exercisable immediately at $0.0001 per share).
- Placement Agent Fees: 8.0% cash fee of gross proceeds plus warrants equal to 6.0% of the aggregate securities sold (exercise price at 125% of offering price).
- Use of Proceeds: General corporate purposes, working capital, and clinical development of the VenoValve.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with a fund managed by Perceptive Advisors. The transaction is priced at the market under Nasdaq rules. The closing is expected on or about September 9, 2021. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Guidance, Risks, and Restrictions
- Lock-up Provisions: The Company is prohibited from issuing common stock or equivalents for 50 days post-closing and from engaging in variable rate transactions for six months post-closing.
- Regulatory Status: The Company is an emerging growth company. The offering utilizes a shelf registration statement (File No. 333-237592) declared effective in April 2020.
- Management Commentary: Proceeds are specifically earmarked to support the clinical development of the VenoValve product.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received (expected ~$18.2 million).
- Confirm the exercise of Pre-Funded Warrants and the resulting increase in share count.
- Review the impact of the 6.0% placement agent warrants on future dilution.
- Monitor the 50-day and 6-month trading restrictions on future equity issuances.
- Check subsequent filings for updates on the VenoValve clinical development progress funded by this capital raise.